CANCER THERAPY MARKET ANALYSIS

Key Developments

• On March 7, 2024, Bristol Myers Squibb Company, a biopharmaceutical company, announced that the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with cisplatin and gemcitabine, for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), the most common type of bladder cancer.
• In February, 2023, TVM Capital Life Science, a life science investment firm, announced that it will invest up to USD 24 million in the newly formed U.S.-based biotechnology company, Recurv Pharma, Inc., through its fund TVM Life Science Innovation II SCSp ("TVM LSI II"). Recurv intends to develop and test a novel taxane therapy for the treatment of solid tumors. Recurv Pharma, Inc. has potential drugs in its pipeline for the treatment of several cancer including colorectal cancer.
• In November, 2022, AstraZeneca, a pharmaceutical company, announced that the U.S. Food and Drug Administration had approved IMFINZI (durvalumab) in combination with IMJUDO (tremelimumab) plus platinum-based chemotherapy in the U.S. for the treatment of adult patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC) based on phase 3 clinical trial
• In November 2022, National Brain Tumor Society (NBTS), a non-profit organization, and IQVIA Inc., a global provider of advanced analytics, technology solutions, and clinical research services, announced that both companies had collaborated for the development of DNA damage repair inhibitors for malignant brain tumors
• In September 2022, Euronext, the world leader in particle accelerator technology, and the Belgian Nuclear Research Centre, a research center, announced the research and development strategic partnership named Pantera to secure the large-scale production of actinium-225 (^225Ac), the alpha-emitting radioisotopes to fight cancers. By working towards this large-scale production, Pantera’s ultimate goal is to improve the accessibility of a future innovative cancer therapy based on ^225Ac.
• In March 2022, Novartis AG, a biopharmaceutical company, announced that the U.S. Food and Drug Administration had approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body (metastatic)
• In January 2021, AstraZeneca, a pharmaceutical company, announced that they had received an approval from U.S. Food and drug Administration, for Enhertu for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen

*Definition: Cancer therapy refers to the use of various treatments such as surgery, radiation, medications, and other therapies to cure cancer, shrink tumors, or stop cancer progression. These treatments include chemotherapy, radiation therapy, immunotherapy, hormone therapy, targeted drug therapy, bone marrow transplants, cryoablation, radiofrequency ablation, and participation in clinical trials.